Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

NCT07456696 is registered in ClinicalTrials.gov with Transcend Therapeutics as lead sponsor.

NCT NCT07456696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07456696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Lead sponsor
Transcend Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
April 2, 2026
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder